1. The kisspeptin-1 receptor antagonist peptide-234 aggravates uremic cardiomyopathy in a rat model
- Author
-
Hoa Dinh, Zsuzsanna Z. A. Kovács, Fanni Márványkövi, Merse Kis, Klaudia Kupecz, Gergő Szűcs, Marah Freiwan, Gülsüm Yilmaz Lauber, Eylem Acar, Andrea Siska, Katalin Eszter Ibos, Éva Bodnár, András Kriston, Ferenc Kovács, Péter Horváth, Imre Földesi, Gábor Cserni, Bruno K. Podesser, Peter Pokreisz, Attila Kiss, László Dux, Krisztina Csabafi, and Márta Sárközy
- Subjects
Medicine ,Science - Abstract
Abstract Uremic cardiomyopathy is characterized by diastolic dysfunction, left ventricular hypertrophy (LVH), and fibrosis. Dysregulation of the kisspeptin receptor (KISS1R)-mediated pathways are associated with the development of fibrosis in cancerous diseases. Here, we investigated the effects of the KISS1R antagonist peptide-234 (P234) on the development of uremic cardiomyopathy. Male Wistar rats (300–350 g) were randomized into four groups: (i) Sham, (ii) chronic kidney disease (CKD) induced by 5/6 nephrectomy, (iii) CKD treated with a lower dose of P234 (ip. 13 µg/day), (iv) CKD treated with a higher dose of P234 (ip. 26 µg/day). Treatments were administered daily from week 3 for 10 days. At week 13, the P234 administration did not influence the creatinine clearance and urinary protein excretion. However, the higher dose of P234 led to reduced anterior and posterior wall thicknesses, more severe interstitial fibrosis, and overexpression of genes associated with left ventricular remodeling (Ctgf, Tgfb, Col3a1, Mmp9), stretch (Nppa), and apoptosis (Bax, Bcl2, Casp7) compared to the CKD group. In contrast, no significant differences were found in the expressions of apoptosis-associated proteins between the groups. Our results suggest that the higher dose of P234 hastens the development and pathophysiology of uremic cardiomyopathy by activating the fibrotic TGF-β-mediated pathways.
- Published
- 2023
- Full Text
- View/download PDF